PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase-Reference-Cited by-同舟云学术

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Published:2017-04-27 Issue:17 Volume:129 Page:2437-2442
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kwong Yok-Lam¹^ORCID,Chan Thomas S. Y.¹,Tan Daryl²³,Kim Seok Jin⁴,Poon Li-Mei⁵,Mow Benjamin⁶,Khong Pek-Lan⁷,Loong Florence⁸,Au-Yeung Rex⁸,Iqbal Jabed⁹,Phipps Colin²³,Tse Eric¹

Affiliation:

1. Department of Medicine, Queen Mary Hospital, Hong Kong;

2. Raffles Cancer Center, Raffles Hospital, Singapore;

3. Department of Haematology, Singapore General Hospital, Singapore;

4. Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;

5. Department of Hematology/Oncology, National University Cancer Institute, Singapore;

6. Mow Blood and Cancer Clinic, Mount Elizabeth Medical Center, Singapore;

7. Department of Diagnostic Radiology, and

8. Department of Pathology, Queen Mary Hospital, Hong Kong; and

9. Department of Anatomic Pathology, Singapore General Hospital, Singapore

Abstract

Key Points NK/T-cell lymphomas failing L-asparaginse, generally fatal, showed a high CR rate to PD1 blockade with pembrolizumab. Comprehensive clinical, radiologic, pathologic, and molecular assessments showed different patterns of CRs and PRs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/17/2437/1399914/blood756841.pdf

Reference21 articles.

1. How I treat NK/T-cell lymphomas;Tse;Blood,2013

2. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study;Yamaguchi;J Clin Oncol,2011

3. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group;Kwong;Blood,2012

4. Diagnosis and management of extranodal NK/T cell lymphoma nasal type;Tse;Expert Rev Hematol,2016

5. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target;Tse;Exp Mol Med,2015

Cited by 401 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From the midfacial destructive drama to the unfolding EBV story: a short history of EBV-positive NK-cell and T-cell lymphoproliferative diseases;Pathology;2024-10

2. Predictive value of pre-treatment T lymphocyte subsets in patients with extranodal natural killer/T-cell lymphoma;Annals of Hematology;2024-08-28

3. Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma;Chinese Medical Journal;2024-08-23

4. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma;Cancer Letters;2024-08